These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1553795)

  • 1. Protection by a polyvalent vaccine against challenge infection and pyelonephritis.
    Kruze D; Biro K; Holzbecher K; Andrial M; Bossart W
    Urol Res; 1992; 20(2):177-81. PubMed ID: 1553795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.
    Moayeri N; Collins CM; O'Hanley P
    Infect Immun; 1991 Oct; 59(10):3778-86. PubMed ID: 1894376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
    Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization against retrograde pyelonephritis. III. Vaccination against chronic pyelonephritis due to Escherichia coli.
    Brooks SJ; Lyons JM; Braude AI
    J Infect Dis; 1977 Nov; 136(5):633-9. PubMed ID: 335001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immobilizing antibodies in urine. II. Prevention of ascending spread of Proteus mirabilis.
    Pazin GJ; Braude AI
    Invest Urol; 1974 Sep; 12(2):129-33. PubMed ID: 4604561
    [No Abstract]   [Full Text] [Related]  

  • 7. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
    Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
    Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against experimental Proteus mirabilis pyelonephritis in rats and significance of immunity.
    Larsson P; Kaijser B; Olling S; Akerlund AS
    Acta Pathol Microbiol Scand C; 1978 Oct; 86C(5):215-20. PubMed ID: 31056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
    Pecha B; Low D; O'Hanley P
    J Clin Invest; 1989 Jun; 83(6):2102-8. PubMed ID: 2566625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
    Scavone P; Miyoshi A; Rial A; Chabalgoity A; Langella P; Azevedo V; Zunino P
    Microbes Infect; 2007 Jun; 9(7):821-8. PubMed ID: 17540603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization against retrograde pyelonephritis. II. Prevention of retrograde Escherichia coli pyelonephritis with vaccines.
    Brooks SJ; Lyons JM; Braude AI
    Am J Pathol; 1974 Feb; 74(2):359-64. PubMed ID: 4590646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of vaccination in urinary infections caused by Escherichia coli in rats].
    Mathieu D; Jacques L; Auer J; Bizzini B
    Biomed Pharmacother; 1987; 41(8):442-5. PubMed ID: 3330459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model.
    Choubini E; Habibi M; Khorshidi A; Ghasemi A; Asadi Karam MR; Bouzari S
    Mol Immunol; 2018 Apr; 96():88-97. PubMed ID: 29525454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice.
    Sabharwal N; Chhibber S; Harjai K
    Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary antibody response after immunisation with a vaccine against urinary tract infection.
    Kruze D; Holzbecher K; Andrial M; Bossart W
    Urol Res; 1989; 17(6):361-6. PubMed ID: 2623792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of immunization with Escherichia coli J5 on the course of experimental pyelonephritis in rats].
    Straube E; Naumann G; Broschewitz U
    Z Urol Nephrol; 1988 Apr; 81(4):247-55. PubMed ID: 3041706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
    Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
    Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
    Habibi M; Asadi Karam MR; Bouzari S
    Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of immunization with K1-antigen of Escherichia coli on the course of experimental urinary tract infection in the rat].
    Straube E; Nimmich W; Broschewitz U; Naumann G
    Z Urol Nephrol; 1986 Jun; 79(6):335-46. PubMed ID: 3529745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.